WO2006012641A3 - Methods for detecting and treating autoimmune disorders - Google Patents

Methods for detecting and treating autoimmune disorders Download PDF

Info

Publication number
WO2006012641A3
WO2006012641A3 PCT/US2005/026915 US2005026915W WO2006012641A3 WO 2006012641 A3 WO2006012641 A3 WO 2006012641A3 US 2005026915 W US2005026915 W US 2005026915W WO 2006012641 A3 WO2006012641 A3 WO 2006012641A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
autoimmune disease
detecting
autoimmune disorders
treating autoimmune
Prior art date
Application number
PCT/US2005/026915
Other languages
French (fr)
Other versions
WO2006012641A2 (en
Inventor
Arthur A Vandenbark
Halina Offner
Richard Bartholomew
Original Assignee
Univ Oregon Health & Science
Us Gov Veterans Affairs
Immune Response Corp Inc
Arthur A Vandenbark
Halina Offner
Richard Bartholomew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Us Gov Veterans Affairs, Immune Response Corp Inc, Arthur A Vandenbark, Halina Offner, Richard Bartholomew filed Critical Univ Oregon Health & Science
Priority to EP05803838A priority Critical patent/EP1786465A4/en
Priority to CA002575604A priority patent/CA2575604A1/en
Priority to US11/658,834 priority patent/US8053197B2/en
Publication of WO2006012641A2 publication Critical patent/WO2006012641A2/en
Publication of WO2006012641A3 publication Critical patent/WO2006012641A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Abstract

The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.
PCT/US2005/026915 2004-07-30 2005-07-29 Methods for detecting and treating autoimmune disorders WO2006012641A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05803838A EP1786465A4 (en) 2004-07-30 2005-07-29 Methods for detecting and treating autoimmune disorders
CA002575604A CA2575604A1 (en) 2004-07-30 2005-07-29 Methods for detecting and treating autoimmune disorders
US11/658,834 US8053197B2 (en) 2004-07-30 2005-07-29 Methods for detecting and treating autoimmune disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59243104P 2004-07-30 2004-07-30
US60/592,431 2004-07-30
US66782005P 2005-04-01 2005-04-01
US60/667,820 2005-04-01

Publications (2)

Publication Number Publication Date
WO2006012641A2 WO2006012641A2 (en) 2006-02-02
WO2006012641A3 true WO2006012641A3 (en) 2007-12-13

Family

ID=35786782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026915 WO2006012641A2 (en) 2004-07-30 2005-07-29 Methods for detecting and treating autoimmune disorders

Country Status (4)

Country Link
US (1) US8053197B2 (en)
EP (1) EP1786465A4 (en)
CA (1) CA2575604A1 (en)
WO (1) WO2006012641A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020363A2 (en) * 2004-07-21 2006-02-23 Illumina, Inc. Method and apparatus for drug product tracking using encoded optical identification elements
EP2392675A1 (en) * 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IFNG gene
US20080131441A1 (en) 2006-09-26 2008-06-05 Manikkam Suthanthiran Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection
GB0718160D0 (en) * 2007-09-18 2007-10-24 Medical Res Council Methods
US8951793B2 (en) * 2008-08-21 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of making an isolated population of FOXP3+ regulatory T cells
DK2618835T3 (en) * 2010-09-20 2017-08-28 Biontech Cell & Gene Therapies Gmbh ANTIGEN-SPECIFIC T-CELL RECEPTORS AND T-CELL EPITOPES
US20140322188A1 (en) * 2013-04-26 2014-10-30 Enzo Biochem, Inc. Tolerizing treatments for autoimmune disease
US20170232084A1 (en) 2013-04-26 2017-08-17 Enzo Biochem Inc. Immune modulation for the treatment of age-related macular degeneration
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US20210009651A1 (en) 2018-03-02 2021-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Se Use of il-34 to treat retinal inflammation and neurodegeneration
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP7391038B2 (en) * 2018-04-18 2023-12-04 ユーシーエル ビジネス リミテッド Methods for enhancing the suppressive properties of Treg cells
US20210382050A1 (en) * 2018-10-19 2021-12-09 The Regents Of The University Of Michigan Method for monitoring autoimmune disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190665A1 (en) * 2000-05-12 2003-10-09 Oregon Health And Science University Methods of selecting T cell receptor V peptides for therapeutic use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US6039947A (en) 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US6113903A (en) 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US5612035A (en) 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes
IL99754A (en) 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical composition containing an autoantigen or a fragment or analogue thereof for the treatment of autoimmune arthritis and multiple sclerosis
US6045796A (en) 1992-12-17 2000-04-04 Anergen, Inc. Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
EP0688223A4 (en) 1993-03-12 1998-05-13 Cellcor Inc -i(IN VITRO) ASSAY MEASURING DEGREE OF ACTIVATION OF IMMUNE CELLS
US5856446A (en) 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
JPH10175854A (en) 1996-10-18 1998-06-30 Dokutaazu Kosumeteikusu:Kk External preparation for skin for improving water (of chinese medicine idea)
IL137904A0 (en) 1998-02-23 2001-10-31 Neurocrine Biosciences Inc Peptide analogues of insulin and pharmaceutical compositions containing the same
JP4601166B2 (en) 1998-05-11 2010-12-22 ミルテニィ バイオテック ゲーエムベーハー Method for directly selecting antigen-specific T cells
DE19821289A1 (en) 1998-05-13 1999-11-18 Volkmar Schoellhorn Method for determining the activity of human and animal cells, in particular blood cells, and microtiter plates
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
AU1855201A (en) 1999-11-02 2001-05-14 Schering Aktiengesellschaft 18-nor-steroids as selectively active estrogens
US20020107388A1 (en) * 2000-05-12 2002-08-08 Vandenbark Arthur A. Methods of identifying and monitoring disease-associated T cells
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
DE60228477D1 (en) 2001-05-08 2008-10-02 Darwin Molecular Corp PROCESS FOR REGULATING THE IMMUNE FUNCTION IN PRIMATES USING THE FOXP3 PROTEIN
JP2006503110A (en) * 2002-10-09 2006-01-26 トーラーレックス， インク． Molecules that selectively bind to effector T cells or regulatory T cells and methods of use thereof
US20050186207A1 (en) * 2004-01-08 2005-08-25 The Regents Of The University Of California Regulatory T cells suppress autoimmunity
AU2005302425A1 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190665A1 (en) * 2000-05-12 2003-10-09 Oregon Health And Science University Methods of selecting T cell receptor V peptides for therapeutic use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRONSKI: "Novel Insights in the Regulation of the Immune System: A Report on the FASEB Summer Research Conference on Autoimmunity", REV. DIABET. STUD., vol. 1, no. 1, 2004, pages 47 - 50, XP008091890 *
See also references of EP1786465A4 *

Also Published As

Publication number Publication date
CA2575604A1 (en) 2006-02-02
US8053197B2 (en) 2011-11-08
WO2006012641A2 (en) 2006-02-02
EP1786465A2 (en) 2007-05-23
EP1786465A4 (en) 2009-01-21
US20090010885A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2006105527A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2006106311A3 (en) Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2007075592A3 (en) Materials and methods for treating chronic fibrotic disease
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007019153A3 (en) Methods for treating hypertension
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006131874A3 (en) Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2006133374A3 (en) Methods for treating shock
WO2007047205A8 (en) Enzyme inhibitors of pai-1
WO2006071456A3 (en) Inhibition of hsp27 phosphorylation for treatment of blistering disorders
WO2006121995A3 (en) Methods for treating nephrolithiasis
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
WO2007084599A3 (en) Methods of increasing lymphatic function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2575604

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005803838

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005803838

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11658834

Country of ref document: US